Biopharma Updates Across the World

This recent post on Biopharmatoday sheds some light on recent biopharma developments from around the world including India, China, Japan, and around the Pacific. Some of the highlights from the article include President Gloria Macapagal-Arroyo from the Philippines signing a new legislation that will transform the nation's top regulatory group. Under the new Act the Bureau of Food and Drugs will replace the Food and Drug Administration. In Europe, Roche became the first multinational pharma company to establish a research and development center in China.

Make sure to take a look at the post for the rest of the updates.

Share this article with your social network, just click below to share now!

Share |

Web Seminar: The Role of PharmEcovigilance in Reducing the Environmental Footprint of Pharmaceuticals

We'd like to remind you about the web seminar for the Green Pharma Summit

Web Seminar: The Role of PharmEcovigilance in Reducing the Environmental Footprint of Pharmaceuticals

Ilene S Ruhoy, MD, PhD, Assistant Professor, Touro University and US EPA Environmental Sciences Division

Tuesday, April 14, 2009 12:00 PM - 1:00 PM EDT

The prescribing and usage of medications have ramifications extending far beyond conventional medical care. The pharmaceutical and healthcare industries have an environmental footprint because the active pharmaceutical ingredients (APIs) can enter the environment as contaminants by a variety of routes, primarily from excretion, bathing, and disposal. Disposal of unwanted, leftover medications by flushing into sewers has been considered a secondary route - - one that supposedly does not contribute substantially to overall environmental loadings of APIs. This presentation is an examination of secondary routes of API release to the environment and for direct but unintentional human exposure. These routes include: (a) bathing, washing, and laundering, and (b) disposal of unused and partially used high-content medical devices. Understanding these secondary routes is important from the perspective of pollution prevention, as well as for reducing the incidence of unintentional and purposeful poisonings of humans and pets, and for improving the quality and cost-effectiveness of healthcare.

Sign up here:
https://www1.gotomeeting.com/register/909165450

Use priority code:G1M1481W1Blog/LI

Share this article with your social network, just click below to share now!

Share |

Biosimilars Bill Offers New Hope

This post on Pharmafocus discusses that the US has gotten a step closer to being able to market generic verions of biologic drugs in the USA for the first time, if the Pathway for Biosimilars Act is passed. Europe has seen a similar legislation pass in 2003, but now the Obama administration seems determined to bring biosimilars here in the US to reduce on healthcare costs. There is much skepticism though as many people say that biosimilars do not behave the same way as originator drugs when it comes to safety and efficacy. What is your take?

If you’re interested in connecting with other professionals in the Biosimilars field, join us at LinkedIn.

Share this article with your social network, just click below to share now!

Share |

Pharma's pressure to be socially responsible

Future Pharmaceutical recently wrote a article on the variety of ways that Pharma companies are choosing to both protect the environment and show their involvement in both humanitarian and environmental projects. Some of the companies in the article have started using green vehicles for distribution and transportation. Others have made efforts to make meetings greener and another option is to choose sustainable suppliers and sustainable distribution centers.

If you're interested in joining a community of Pharma professionals who are committed to make their Pharma projects that protect the enviornment and are sustainable, join us at the Green Pharma LinkedIn group.

Share this article with your social network, just click below to share now!

Share |